Last reviewed · How we verify
escitalopram and sertraline
Both escitalopram and sertraline are selective serotonin reuptake inhibitors (SSRIs) that increase serotonin availability in the brain by blocking its reabsorption at the synaptic cleft.
Both escitalopram and sertraline are selective serotonin reuptake inhibitors (SSRIs) that increase serotonin availability in the brain by blocking its reabsorption at the synaptic cleft. Used for Major depressive disorder, Generalized anxiety disorder, Panic disorder.
At a glance
| Generic name | escitalopram and sertraline |
|---|---|
| Sponsor | Oregon Health and Science University |
| Drug class | Selective serotonin reuptake inhibitor (SSRI) |
| Target | Serotonin transporter (SERT) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Mental Health |
| Phase | FDA-approved |
Mechanism of action
SSRIs work by inhibiting the serotonin transporter (SERT), preventing the reuptake of serotonin from the synaptic space back into presynaptic neurons. This increases serotonin concentration in the synapse, enhancing serotonergic neurotransmission. Both drugs are commonly used to treat depression and anxiety disorders, though they are typically prescribed as monotherapies rather than in combination.
Approved indications
- Major depressive disorder
- Generalized anxiety disorder
- Panic disorder
- Obsessive-compulsive disorder
- Post-traumatic stress disorder
- Social anxiety disorder
Common side effects
- Nausea
- Headache
- Insomnia
- Sexual dysfunction
- Diarrhea
- Dry mouth
- Somnolence
Key clinical trials
- TDM-Guided Treatment With SSRIs in Hospitalized Adults and Children (PHASE4)
- Pattern Separation in Major Depressive Disorder (PHASE1)
- Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure (PHASE3)
- Treating Negative Affect in Low Back Pain Patients (PHASE2, PHASE3)
- Effect of SC-ICBT for Adults With OCD：A Three-Arm Randomized Controlled Trial (NA)
- Neurobiological and Genomic Predictors of Relapse in Depression
- Multiple Ascending Dose Phase 1 Study of ALA-3000 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- escitalopram and sertraline CI brief — competitive landscape report
- escitalopram and sertraline updates RSS · CI watch RSS
- Oregon Health and Science University portfolio CI